Open AccessA Prospective Trial of Nebulized Amikacin in the Treatment of Bronchiectasis Exacerbation
Author(s) -
Yirepanjaing Ailiyaer,
Xiuxiu Wang,
Yan Zhang,
Caiyu Li,
Tao Li,
Qian Qi,
Yu Li
Publication year - 2018
Publication title -
respiration
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.264
H-Index - 81
eISSN - 1423-0356
pISSN - 0025-7931
DOI - 10.1159/000486134
Subject(s) - medicine , bronchiectasis , exacerbation , amikacin , prospective cohort study , intensive care medicine , asthma exacerbations , anesthesia , emergency medicine , asthma , lung , antibiotics , microbiology and biotechnology , biology
Pseudomonas aeruginosa is the most common pathogenic bacteria in bronchiectasis (BE) patients. The availability and security of nebulized amikacin treatment are unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom